Results 191 to 200 of about 30,994 (308)

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. [PDF]

Indian J Med Res
Gupta M, Shukla J.
europepmc   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8172-8188, September 2026.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

Epithelial TMPRSS2 impairs glucose homeostasis in obese mice by regulating ghrelin-GLP-1 receptor signaling pathway. [PDF]

JCI Insight
Kaur D, Chakrabarty S, Witzler C, Wang H, Wang M, Wolz R, Wilgenbus P, Posma JJ, Rachakonda S, Marini F, Zinina VV, Reyda S, Gogiraju R, Graf C, Samad F, Schäfer K, Reinhardt C, Soshnikova N, Ruf W, Madhusudhan T.   +19 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Epidemiological study of gastrointestinal parasites in yaks (<i>Bos grunniens</i>) from the Ganzi Tibetan autonomous prefecture, Sichuan Province, China. [PDF]

Parasite Epidemiol Control
Ahmed M, Pan Y, Wang L, Li Y, Qi J, Lan L, Zuo Z, Xie Y.   +7 more
europepmc   +1 more source

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7768-7778, September 2026.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source

Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial.

JAMA Intern Med
Ahmad AI, Garg S, Jacobs J, Ansari Z, Al-Din TJ, Almomani A, Valencia S, Vargo J, Chatterjee A, Siddiki H, Hong L, Nicolas MA, Miller A, Shah T.   +13 more
europepmc   +1 more source

Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders. [PDF]

Diabetes Metab Syndr Obes
Qiao Y, Zhou F, Mao T, Gao L.
europepmc   +1 more source

GIP Gene [PDF]

, 2020
openaire   +1 more source

Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population‐Based Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8460-8468, September 2026.
ABSTRACT Aims This study aimed to analyse incident glucose lowering drug (GLD) utilisation in Australia between the period 2014 and 2024. Materials and Methods Australian Pharmaceutical Benefits Scheme (PBS) data (10% PBS dataset) were analysed to assess the proportions of incident monotherapy, dual therapy and triple therapy and the proportion of ...
Peter S. Hamblin, Stella Talic, Harvey J. W. Koh, Arul Earnest, Anthony W. Russell, Sophia Zoungas   +5 more
wiley   +1 more source